|
|
|
|
|
||
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online August 3, 2005
doi: 10.1242/10.1242/jcs.02482
Research Article |
1 Animal Genomics, AgResearch, Private Bag 3123, East Street, Hamilton, New Zealand
2 School of Biological Sciences, University of Waikato, Private Bag 3105, Hamilton, New Zealand
Author for correspondence (e-mail: ravi.kambadur{at}agresearch.co.nz)
Accepted 10 May 2005
Numerous stimulatory growth factors that can influence muscle regeneration are known. Recently, it has been demonstrated that neutralization of muscle growth inhibitory factors, such as myostatin (Mstn; also known as growth differentiation factor 8, Gdf8), also leads to increased muscle regeneration in mdx mice that are known to have cycles of degeneration. However, the precise mechanism by which Mstn regulates muscle regeneration has not yet been fully determined. To investigate the role of Mstn in adult skeletal muscle regeneration, wild-type and myostatin-null (Mstn-/-) mice were injured with notexin. Forty-eight hours after injury, accelerated migration and enhanced accretion of myogenic cells (MyoD1+) and macrophages (Mac-1+) was observed at the site of regeneration in Mstn-/- muscle as compared with wild-type muscle. Inflammatory cell numbers decreased more rapidly in the Mstn-/- muscle, indicating that the whole process of inflammatory cell response is accelerated in Mstn-/- mice. Consistent with this result, the addition of recombinant Mstn reduced the activation of satellite cells (SCs) and chemotactic movements of both myoblasts and macrophages ex vivo. Examination of regenerated muscle (28 days after injury) also revealed that Mstn-/- mice showed increased expression of decorin mRNA, reduced fibrosis and improved healing as compared with wild-type mice. On the basis of these results, we propose that Mstn negatively regulates muscle regeneration not only by controlling SC activation but also by regulating the migration of myoblasts and macrophages to the site of injury. Thus, antagonists of Mstn could potentially be useful as pharmacological agents for the treatment of disorders of overt degeneration and regeneration.
Key words: Myostatin, Satellite cell, Muscle regeneration, Fibrosis, Decorin, Macrophages
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Amthor, A. Otto, A. Vulin, A. Rochat, J. Dumonceaux, L. Garcia, E. Mouisel, C. Hourde, R. Macharia, M. Friedrichs, et al. Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity PNAS, May 5, 2009; 106(18): 7479 - 7484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hennebry, C. Berry, V. Siriett, P. O'Callaghan, L. Chau, T. Watson, M. Sharma, and R. Kambadur Myostatin regulates fiber-type composition of skeletal muscle by regulating MEF2 and MyoD gene expression Am J Physiol Cell Physiol, March 1, 2009; 296(3): C525 - C534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N Artaza and K. C Norris Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells J. Endocrinol., February 1, 2009; 200(2): 207 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Souza, X. Chen, Y. Guo, P. Sava, J. Zhang, J. J. Hill, P. J. Yaworsky, and Y. Qiu Proteomic Identification and Functional Validation of Activins and Bone Morphogenetic Protein 11 as Candidate Novel Muscle Mass Regulators Mol. Endocrinol., December 1, 2008; 22(12): 2689 - 2702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lara-Pezzi, L. E. Felkin, E. J. Birks, P. Sarathchandra, K. D. Panse, R. George, J. L. Hall, M. H. Yacoub, N. Rosenthal, and P. J. R. Barton Expression of Follistatin-Related Genes Is Altered in Heart Failure Endocrinology, November 1, 2008; 149(11): 5822 - 5827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Rodgers and D. K. Garikipati Clinical, Agricultural, and Evolutionary Biology of Myostatin: A Comparative Review Endocr. Rev., August 1, 2008; 29(5): 513 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. B. Li, H. D. Kollias, and K. R. Wagner Myostatin Directly Regulates Skeletal Muscle Fibrosis J. Biol. Chem., July 11, 2008; 283(28): 19371 - 19378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N Artaza, R. Singh, M. G Ferrini, M. Braga, J. Tsao, and N. F Gonzalez-Cadavid Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/2 cells without affecting their differentiation into myofibroblasts J. Endocrinol., February 1, 2008; 196(2): 235 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhu, Y. Li, W. Shen, C. Qiao, F. Ambrosio, M. Lavasani, M. Nozaki, M. F. Branca, and J. Huard Relationships between Transforming Growth Factor-beta1, Myostatin, and Decorin: IMPLICATIONS FOR SKELETAL MUSCLE FIBROSIS J. Biol. Chem., August 31, 2007; 282(35): 25852 - 25863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N Artaza, S. Reisz-Porszasz, J. S Dow, R. A Kloner, J. Tsao, S. Bhasin, and N. F Gonzalez-Cadavid Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse J. Endocrinol., July 1, 2007; 194(1): 63 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Stoick-Cooper, R. T. Moon, and G. Weidinger Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine Genes & Dev., June 1, 2007; 21(11): 1292 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bardella, D. Dettori, M. Olivero, N. Coltella, M. Mazzone, and M. F. Di Renzo The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo Clin. Cancer Res., April 1, 2007; 13(7): 2191 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yang, Y. Zhang, Y. Li, Z. Wu, and D. Zhu Myostatin Induces Cyclin D1 Degradation to Cause Cell Cycle Arrest through a Phosphatidylinositol 3-Kinase/AKT/GSK-3beta Pathway and Is Antagonized by Insulin-like Growth Factor 1 J. Biol. Chem., February 9, 2007; 282(6): 3799 - 3808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Mendias, J. E. Marcin, D. R. Calerdon, and J. A. Faulkner Contractile properties of EDL and soleus muscles of myostatin-deficient mice J Appl Physiol, September 1, 2006; 101(3): 898 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Shi and D. J. Garry Muscle stem cells in development, regeneration, and disease. Genes & Dev., July 1, 2006; 20(13): 1692 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Parsons, D. P. Millay, M. A. Sargent, E. M. McNally, and J. D. Molkentin Age-Dependent Effect of Myostatin Blockade on Disease Severity in a Murine Model of Limb-Girdle Muscular Dystrophy Am. J. Pathol., June 1, 2006; 168(6): 1975 - 1985. [Abstract] [Full Text] [PDF]
|
|
